Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows From Operating Activities:
Net loss	$ (6,577,816)	$ (6,420,341)
Adjustments to reconcile net loss to cash used in operating activities
Change in fair value of warrant liability	(858)	(20,722)
Change in fair value of investment option liability	(1,707)	(18,664)
Stock-based compensation	587,089	1,090,716
Amortization of intangibles	42,180	126,564
Depreciation expense	119,193	128,438
Other	(128,683)
Change in operating assets and liabilities:
Prepaid expenses and other current assets	132,795	(3,674)
Accounts payable, accrued expenses and other current liabilities	(295,982)	(1,296,907)
Due to related parties	(232,891)
Net cash used in operating activities	(6,356,680)	(6,414,590)
Cash Flows From Financing Activities:
Proceeds from sale of Common Stock and warrants, net of offering costs	4,244,467
Proceeds from Common Stock sold for cash pursuant to the ATM Agreement, net of offering costs	1,636,799
Proceeds from the exercise of warrants, net of offering costs	2,009,095	2,676,980
Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options		1,804,819
Proceeds from Common Stock sold under the Equity Distribution Agreement, net of offering costs		2,290,186
Proceeds from Common Stock sold under the Purchase Agreement, net of offering costs		599,862
Payment for offering costs previously accrued		(161,461)
Net cash provided by financing activities	7,890,361	7,210,386
Effect of foreign exchange rate on changes on cash	(17,113)	27,910
Net increase in cash	1,516,568	823,706
Cash at beginning of period	2,241,026	2,287,977
Cash at end of period	3,757,594	3,111,683
Supplemental disclosure of cash flow transactions:
Cash paid for interest
Income taxes paid	3,000	24,001
Non-cash financing and investing activities:
Non-cash issuance of round-up shares	73
Non-cash issuance of RSA vested shares	12
Offering costs accrued not paid	49,837	35,455
Deferred offering costs not paid	33,624
Deemed dividend on inducement of warrants	1,513,449
Issuance of Placement Agent Warrants as offering costs	237,564
Issuance of common shares for offering costs		771,293
Deferred offering costs charged to offering costs		$ 495,544

Enveric Biosciences, Inc. 10-Q